0
     

Report Added
Report already added
T-Cell Immunotherapy Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

T-Cell Immunotherapy Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

Summary

Further key aspects of the report indicate that:
Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology
Chapter 2: Global Industry Summary
Chapter 3: Market Dynamics
Chapter 4: Global Market Segmentation by region, type and End-Use
Chapter 5: North America Market Segmentation by region, type and End-Use
Chapter 6: Europe Market Segmentation by region, type and End-Use
Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use
Chapter 8: South America Market Segmentation by region, type and End-Use
Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.
Chapter 10: Market Competition by Companies
Chapter 11: Market forecast and environment forecast.
Chapter 12: Industry Summary.

The global T-Cell Immunotherapy market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for are the significant development of demand and improvement of COVID-19 and geo-economics.

Based on the type of product, the global T-Cell Immunotherapy market segmented into
CAR-T
TCR
TIL Therapies

Based on the end-use, the global T-Cell Immunotherapy market classified into
Stomach Cancer
Lung Cancer
Colorectal Cancer
Esophagus Cancer
Pancreatic Cancer
Others

Based on geography, the global T-Cell Immunotherapy market segmented into
North America [U.S., Canada, Mexico]
Europe [Germany, UK, France, Italy, Rest of Europe]
Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
South America [Brazil, Argentina, Rest of Latin America]
Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]

And the major players included in the report are
Adaptimmune
Altor Bioscience Corporation
Cellectis
Juno Therapeutics
Kite Pharma
Novartis
Takara Bio
Unum Therapeutics
Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL T-CELL IMMUNOTHERAPY INDUSTRY
2.1 Summary about T-Cell Immunotherapy Industry
2.2 T-Cell Immunotherapy Market Trends
2.2.1 T-Cell Immunotherapy Production & Consumption Trends
2.2.2 T-Cell Immunotherapy Demand Structure Trends
2.3 T-Cell Immunotherapy Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 CAR-T
4.2.2 TCR
4.2.3 TIL Therapies
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Stomach Cancer
4.3.2 Lung Cancer
4.3.3 Colorectal Cancer
4.3.4 Esophagus Cancer
4.3.5 Pancreatic Cancer
4.3.6 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 CAR-T
5.2.2 TCR
5.2.3 TIL Therapies
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Stomach Cancer
5.3.2 Lung Cancer
5.3.3 Colorectal Cancer
5.3.4 Esophagus Cancer
5.3.5 Pancreatic Cancer
5.3.6 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 CAR-T
6.2.2 TCR
6.2.3 TIL Therapies
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Stomach Cancer
6.3.2 Lung Cancer
6.3.3 Colorectal Cancer
6.3.4 Esophagus Cancer
6.3.5 Pancreatic Cancer
6.3.6 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 CAR-T
7.2.2 TCR
7.2.3 TIL Therapies
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Stomach Cancer
7.3.2 Lung Cancer
7.3.3 Colorectal Cancer
7.3.4 Esophagus Cancer
7.3.5 Pancreatic Cancer
7.3.6 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 CAR-T
8.2.2 TCR
8.2.3 TIL Therapies
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Stomach Cancer
8.3.2 Lung Cancer
8.3.3 Colorectal Cancer
8.3.4 Esophagus Cancer
8.3.5 Pancreatic Cancer
8.3.6 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 CAR-T
9.2.2 TCR
9.2.3 TIL Therapies
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Stomach Cancer
9.3.2 Lung Cancer
9.3.3 Colorectal Cancer
9.3.4 Esophagus Cancer
9.3.5 Pancreatic Cancer
9.3.6 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Adaptimmune
10.1.2 Altor Bioscience Corporation
10.1.3 Cellectis
10.1.4 Juno Therapeutics
10.1.5 Kite Pharma
10.1.6 Novartis
10.1.7 Takara Bio
10.1.8 Unum Therapeutics
10.2 T-Cell Immunotherapy Sales Date of Major Players (2017-2020e)
10.2.1 Adaptimmune
10.2.2 Altor Bioscience Corporation
10.2.3 Cellectis
10.2.4 Juno Therapeutics
10.2.5 Kite Pharma
10.2.6 Novartis
10.2.7 Takara Bio
10.2.8 Unum Therapeutics
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT

List of Table
1.Table T-Cell Immunotherapy Product Type Overview
2.Table T-Cell Immunotherapy Product Type Market Share List
3.Table T-Cell Immunotherapy Product Type of Major Players
4.Table Brief Introduction of Adaptimmune
5.Table Brief Introduction of Altor Bioscience Corporation
6.Table Brief Introduction of Cellectis
7.Table Brief Introduction of Juno Therapeutics
8.Table Brief Introduction of Kite Pharma
9.Table Brief Introduction of Novartis
10.Table Brief Introduction of Takara Bio
11.Table Brief Introduction of Unum Therapeutics
12.Table Products & Services of Adaptimmune
13.Table Products & Services of Altor Bioscience Corporation
14.Table Products & Services of Cellectis
15.Table Products & Services of Juno Therapeutics
16.Table Products & Services of Kite Pharma
17.Table Products & Services of Novartis
18.Table Products & Services of Takara Bio
19.Table Products & Services of Unum Therapeutics
20.Table Market Distribution of Major Players
21.Table Global Major Players Sales Revenue (Million USD) 2017-2020e
22.Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
23.Table Global T-Cell Immunotherapy Market Forecast (Million USD) by Region 2021f-2026f
24.Table Global T-Cell Immunotherapy Market Forecast (Million USD) Share by Region 2021f-2026f
25.Table Global T-Cell Immunotherapy Market Forecast (Million USD) by Demand 2021f-2026f
26.Table Global T-Cell Immunotherapy Market Forecast (Million USD) Share by Demand 2021f-2026f

Report Title: T-Cell Immunotherapy Market Status and Trend Analysis 2017-2026 (COVID-19 Version)


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW